| Name | Diversicare Of Oneonta |
|---|---|
| Location | 215 Valley Road, Oneonta, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 120 |
| Occupancy Rate | 78.92% |
| Medicare ID (CCN) | 015159 |
| Legal Business Name | Diversicare Of Oneonta Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1417402504 |
| Organization Name | DIVERSICARE OF ONEONTA, LLC |
| Doing Business As | DIVERSICARE OF ONEONTA |
| Address | 215 Valley Rd, Oneonta, AL 35121 |
| Phone Number | 205-274-2365 |
News Archive
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.
The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.
Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.
Parenting skills of adults with ADHD improve when their ADHD is treated with medication, according to Penn State College of Medicine researchers.
Zephyr Technology is proud to announce the release of ZephyrLIFE - the world's first remote monitoring system designed specifically for the growing market of transitional care. Transitional care involves managing the continuity of health care during the transition between health care practitioners and facilities as a patient's condition and care needs change during the course of a chronic or acute illness, which ZephyrLIFE has been designed for.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.
The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.
Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.
Parenting skills of adults with ADHD improve when their ADHD is treated with medication, according to Penn State College of Medicine researchers.
Zephyr Technology is proud to announce the release of ZephyrLIFE - the world's first remote monitoring system designed specifically for the growing market of transitional care. Transitional care involves managing the continuity of health care during the transition between health care practitioners and facilities as a patient's condition and care needs change during the course of a chronic or acute illness, which ZephyrLIFE has been designed for.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 1.28 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.63 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.18 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.27 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.55 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 1.06 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.12 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.2 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.16 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 42.11 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.47 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 2.34 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 29.78 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1.01 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.08 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 99.2 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 66.78 | 82.93 |
News Archive
Patients with muscle-invasive bladder cancer have been shown to benefit from chemotherapy prior to surgical removal of the bladder.
The world's most widespread test for ovarian cancer reports false-positives in 94 of 100 diagnosed cases. Now, chemists at the University of Copenhagen working with clinical researchers at University College London have developed a method able to halve the number of false-positives. When fully developed, the new test will spare a significant number of women from unnecessary worry and further testing. Furthermore, global health care providers stand to save substantial sums - just by including a test on a certain sugar molecule in tandem with the currently prevailing diagnostic test.
Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.
Parenting skills of adults with ADHD improve when their ADHD is treated with medication, according to Penn State College of Medicine researchers.
Zephyr Technology is proud to announce the release of ZephyrLIFE - the world's first remote monitoring system designed specifically for the growing market of transitional care. Transitional care involves managing the continuity of health care during the transition between health care practitioners and facilities as a patient's condition and care needs change during the course of a chronic or acute illness, which ZephyrLIFE has been designed for.
› Verified 5 days ago